Abstract #3662

A survey of best practice guidelines to harmonize neuroimaging biomarkers for neurodegenerative diseases

Jorge Jovicich¹, Frederik Barkhof^2,3, Claudio Babiloni⁴, Karl Herholz⁵, Christoph Mullert⁶, Bart N.M. van Berckel⁷, Giovanni B Frisoni^8,9, and SRA-NED JPND Working Group¹

¹Center for Mind/Brain Sciences, University of Trento, Rovereto, Italy, ²VU University Medical Center, Amsterdam, Netherlands, ³Centre for Medical Image Computing, University College London, London, United Kingdom, ⁴Sapienza University of Rome, Rome, Italy, ⁵University of Manchester, Manchester, United Kingdom, ⁶Psychiatry and Psychotherapy University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁷VU University Medical Center Amsterdam, Amsterdam, Netherlands, ⁸Lab Alzheimer’s Neuroimaging & Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy, ⁹Memory Clinic and LANVIE Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland

Current challenges in neurodegenerative diseases (ND): need for early and accurate markers for differential diagnosis, prognosis, progression tracking and intervention assessments.

Big-data neuroimaging studies might help addressing these challenges. However, large-sample neuroimaging data still lacks standardization (multi-vendor acquisition, analysis) and cross –validation (across markers, across large populations), in particular with state-of-the-art MRI hardware (≥32 head RF channel coils and powerful gradients).

Here we: i) evaluate current barriers perceived by the broad neuroimaging research/clinical/industry communities for the large-scale harmonization of MRI/PET-SPECT/EEG neuroimaging methods in the context of ND studies, and ii) propose actions that may help addressing these barriers.

This abstract and the presentation materials are available to members only; a login is required.

Join Here